Meeting
2019 ASCO Annual Meeting
Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.
Authors
Richard M. Stone
Dana-Farber Cancer Institute, Boston, MA
Richard M. Stone , Eunice S. Wang , Aaron David Goldberg , Kendra Lynn Sweet , Amir Tahmasb Fathi , Hongtao Liu , Boo Messahel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03258931
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7068)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7068
Abstract #
TPS7068
Poster Bd #
439b
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naïve patients with FLT3 mutated AML.
First Author: R. M. Stone
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey
Poster
2021 ASCO Annual Meeting
Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
First Author: Vinod Pullarkat
Poster
2018 ASCO Annual Meeting
Trial in progress: An open-label, multicenter, phase 3b study to assess the safety and efficacy of midostaurin in patients (pts) aged ≥ 18 y with newly diagnosed (ND) FLT3-mutated acute myeloid leukemia (AML) who are eligible for 7+3 or 5+2 chemotherapy (chemo).
First Author: Adolfo Fuentes